Science Current Events | Science News | Brightsurf.com
 

Gene therapy kills breast cancer stem cells, boosts chemotherapy

September 13, 2011
Targeted agent avoids healthy cells, blocks proteins that prevent cell death in tumors

HOUSTON -- Gene therapy delivered directly to a particularly stubborn type of breast cancer cell causes the cells to self-destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers at The University of Texas MD Anderson Cancer Center reported in the Sept. 13 edition of Cancer Cell.

In cellular and mouse studies, scientists found the gene mutation BikDD significantly reduced treatment-resistant breast-cancer initiating cells (BCICs), also known as breast cancer stem cells, by blocking the activity of three proteins in the Bcl-2 family. This genetic approach increased the benefits of lapatinib, one of the most common chemotherapy drugs for breast cancer.

"There are no effective methods to target BCICs, and they're urgently needed, especially for relapsed breast cancer patients," said senior author Mien-Chie Hung, Ph.D., vice president for basic research, professor and chair of MD Anderson's Department of Molecular and Cellular Oncology. "This research suggests a potential therapeutic approach to breast cancer stem cells that will minimize recurrence and drug resistance."

Special delivery system targets cells

Gene therapy was deposited directly into breast cancer cells with an innovative delivery system called VISA, short for versatile expression vector, which was developed at MD Anderson. It includes a targeting agent, also called a promoter, two components that boost gene expression in the target tissue and a payload -- a Bik mutant gene called BikDD known to kill cancer cells. It's all packaged in a fatty ball called a liposome and delivered intravenously.

This system has been successfully applied in pancreatic, lung, liver and ovarian cancer preclinical models. MD Anderson clinical researchers are preparing a phase I clinical trial for pancreatic cancer.

Stem cells frequently stymie treatment

Breast cancer stem cells, often resistant to chemotherapy and radiotherapy, are a major obstacle for breast cancer treatment, Hung said. If any of these cells remain after treatment, a new tumor often forms. Although lapatinib, known commercially as Tykerb®, can stabilize the level of these cells, no drugs are available to reduce them.

The Bcl-2 family of proteins - especially the subtypes Bcl-2, Bcl-xL and Mcl-1 -- is essential for breast cancer tumor growth and treatment resistance. If too many of these three proteins are present, they can cause poor prognosis and resistance to chemotherapy drugs including lapatinib, as well as paclitaxel, doxorubicin and cisplatin.

This study shows that Bcl-2 proteins help breast cancer stem cells survive, causing resistance to treatment and likelihood of recurrence. However, using VISA to deliver BikDD can block the three key Bcl-2 proteins, eliminating the stem cells.

VISA-claudin4-BikDD cuts tumor burden

The researchers engineered a VISA that contained claudin4, a protein over-expressed in breast cancer, as a targeting agent to preferentially express BikDD in breast cancer cells. This process silenced the three Bcl-2 proteins and caused the cancer cells to self-destruct. Since the VISA focused the BikDD on cancer cells, normal cells were not affected.

Treating mice with the VISA-claudin4-BikDD therapy reduced tumor volume by 75 percent compared to control mice.

They also compared VISA-claudin4-BikDD therapy to BikDD packaged with a non-specific strong promoter from cytomegalovirus. Both versions reduced tumor burden and extended survival of mice, but tumor volume in mice treated with VISA-claudin4-BikDD was half that of the CMV-BikDD-treated mice. In a safety study using an unusually high dose, 60 percent of mice treated with CMV-BikDD survived after three days; all mice treated with VISA-Claudin4-BikDD survived for the duration of the 14-day safety profile study.

In cell line experiments, the CMV-BikDD also invaded and destroyed normal cells, while the VISA-Claudin4-BikDD did not.

Agent energizes lapatinib, other drugs

BikDD made HER2-positive breast cancer cells more sensitive to lapatinib when all three Bcl-2 proteins were inhibited but not when they were inhibited separately. HER2-positive breast cancer is a particularly aggressive type that makes too much human epidermal growth factor 2; it accounts for about 20 percent of breast cancers. BikDD also sensitized EGFR+ (epidermal growth factor positive) breast cancer cells to lapatinib and several other breast cancer cells lines to paclitaxel.

Moving discovery forward

Hung said this approach is promising for breast cancer treatment, especially recurrent disease.

"VISA-claudin4-BikDD gene therapy may provide an effective strategy to inhibit breast tumor growth," he said. "It demonstrates virtually no toxicity in normal cells and produces a profound killing effect in multiple breast cancer cell lines and synergy with other agents."

Hung said the next step is to move VISA-claudin4-BikDD into a Phase I clinical trial to test its effect on patients with breast cancer.

###

This work was supported by grants from the National Cancer Institute, including MD Anderson's Specialized Program in Research Excellence grant, the MD Anderson/China Medical University Hospital Sister Institution Fund, the Breast Cancer Research Foundation, National Breast Cancer Foundation, Inc., Patel Memorial Breast Cancer Research Fund, MD Anderson's Center for Biological Pathways and NCI Cancer Center Support Grant, and the Taiwan Department of Health Cancer Center Research of Excellence Grant.

In addition to Hung, MD Anderson researchers include first author Jing-Yu Lang, Ph.D., first author, Jennifer Hsu, Ph.D., Chun-Ju Chang, Ph.D., Qingfei Wang, Ph.D., Xiaoming Xie, Ph.D., Yi Bao, Ph.D., Hirohito Yamaguchi, Ph.D. and Dihua Yu, M.D., Ph.D., Department of Molecular and Cellular Oncology; Funda Meric-Bernstam, M.D., Department of Surgical Oncology; Wendy Woodward, M.D., Ph.D., Department of Radiation Oncology; and Gabriel Hortobagyi, M.D., Department of Breast Medical Oncology.

Hung and Hsu hold joint appointments at China Medical University and Asia University, Taichung, Taiwan. Xie holds an appointment at Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For eight of the past 10 years, including 2011, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

University of Texas M. D. Anderson Cancer Center


Related Breast Cancer Current Events and Breast Cancer News Articles


Latest evidence on using hormone replacement therapy for treating menopausal symptoms
Hormone replacement therapy (HRT) is the most effective treatment for menopausal symptoms, in particular for younger women at the onset of the menopause, suggests a new review published today (19 December) in The Obstetrician & Gynaecologist (TOG).

Orphan receptor proteins deliver 2 knock-out punches to glioblastoma cells
Two related proteins exert a lethal double whammy effect against glioblastoma cells when activated with a small molecule, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

Study shows how breast cancer cells break free to spread in the body
More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.

Researchers identify new approach to diagnose blood clots in lungs of patients over 50
Researchers from Intermountain Medical Center in Salt Lake City have identified a new "sliding scale" model used to rule out potentially deadly blood clots in the lungs, known as pulmonary embolisms, that is more accurate than current diagnostic methods.

Too much, too little, just right
Scientists have long known the p53 protein suppresses tumors. However, a recent animal study by UC Davis researchers has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels.

Proteins drive cancer cells to change states
A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.

Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

Herceptin found to improve long-term survival of HER2-positive breast cancer patients
VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute (NCI)-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients.

Migraine was not associated with BC in a pooled analysis of prospective cohort studies
Migraine was not associated with breast cancer risk or differences in the endogenous sex hormones that have been proposed to be associated with migraines, according to a new study published December 12 in the JNCI: Journal of the National Cancer Institute.

Male and female breast cancers are not identical
Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women.
More Breast Cancer Current Events and Breast Cancer News Articles

Let Me Get This Off My Chest: A Breast Cancer Survivor Over-Shares

Let Me Get This Off My Chest: A Breast Cancer Survivor Over-Shares
by Margaret Lesh (Author)


Tamoxifen hot flashes, mastectomy, reconstruction, breast cancer etiquette, Frankenboobs, bras with special attachments—Margaret Lesh shares all in her funny, heartfelt collection of essays, anecdotes, and life lessons from the perspective of a two-time breast cancer survivor. She’ll tell you when it’s okay to play the cancer card, what you should take to the hospital, and gives suggestions on how to cope in those dark moments of the soul. With practical tips sprinkled throughout, LET ME GET THIS OFF MY CHEST explores how breast cancer changed her outlook on life, offering honest insights, humor, and sensitivity as she looks for the silver lining in a not-so-great situation. Whether you are a woman diagnosed with breast cancer or whether you know someone with breast cancer, this...

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer
by John Link (Author)


The updated edition of the essential resource for the 250,000 women diagnosed with breast cancer each yearBreast cancer is the leading cause of death in women from thirty-five to fifty-four years of age, and few things are as terrifying and confusing as a diagnosis of this disease. The fifth edition of The Breast Cancer Survival Manual is a concise, information-packed guide that is newly revised to contain all of the latest findings to help the woman facing treatment feel informed and empowered. John Link, M.D., a pioneer developer of Breastlink Medical Group in Southern California includes the most current medical advice on     • Tamoxifen, Herceptin, and other chemotherapy options      • The growing importance of HER2 oncogene testing      • Clinical research trials...

Cancer: What I Wish I Had Known When I Was First Diagnosed: Tips and Advice From a Survivor

Cancer: What I Wish I Had Known When I Was First Diagnosed: Tips and Advice From a Survivor
by Michele Ryan (Author)


A cancer diagnosis results, understandably, in fear and uncertainty. Once the initial shock passes, the questions begin. Some are medical in nature: What are your treatment options? Some are intensely personal: How do you tell your children? Will your hair grow back after chemo? How will the disease affect your sex life and relationships? In Cancer: What I Wish I Had Known When I Was First Diagnosed, ten-year breast cancer survivor Michele Ryan answers these questions and more. Michele's common sense advice and practical tips provide a comprehensive road map to help navigate the basic challenges of life with cancer. She covers everything from how to evaluate your health insurance to what to pack for hospital stays, all carefully laid out in an easy-to-navigate format so readers can find...

An Inconvenient Year

An Inconvenient Year
by Original Writing


It is a book that deals with the social side of cancer, as a parent, a lover and a friend. It is a story of coping with uncertainty, the reactions of others and living with them too. It documents the total shock and utter fear that a diagnosis brings and the hopelessness of surrendering to a treatment that brings its own baggage yet ultimately insures life. It talks about confronting hair loss along with discovering the more covert assault on all things feminine. Yet at the very root of the book, ahead of the fear and anger, there is humour and laughter. Though the story of cancer has been told before, it has not been told like this"

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)
by Edward Bauman MEd PhD (Author), Helayne Waldman MS EdD (Author), Donald I. Abrams MD (Foreword)


If you’re a breast cancer survivor, chances are you have renewed your commitment to maintaining your good health and taking care of your body. As one of the best preventative measures known to doctors and nutritionists today, a robust, cancer-fighting diet is vital to your personal plan for breast cancer prevention.The Whole-Food Guide for Breast Cancer Survivors is an essential guide for every woman seeking to understand the effect of nutritional deficiencies and environmental factors on her overall health and wellness. Based on Edward Bauman’s groundbreaking Eating for Health model, this highly comprehensive, practical approach can help you reduce the chance of breast cancer recurrence; rebuild your immune system; and enjoy a stronger, healthier body.Reduce the chance of breast...

Fight Now: Eat & Live Proactively Against Breast Cancer

Fight Now: Eat & Live Proactively Against Breast Cancer
by Aaron Tabor, MD


Dr. Tabor’s FIGHT NOW book provides information on lifestyle choices that might improve breast health and overall health. The purpose of Dr. Tabor’s medical research is to empower you to become proactive against breast cancer now with specific food and lifestyle choices. We can make specific food and lifestyle choices to lower the risk of getting breast cancer, risk of recurrence, and risk of dying from breast cancer. The only alternative is to be reactive after you get breast cancer or have a recurrence of breast cancer. The choice is clear

Whether you are currently fighting breast cancer; are a survivor; or, simply trying to lower your risk, Dr. Tabor’s FIGHT NOW book will give you concise, critical information that you can start using today. You don’t have to read...

Beating Breast Cancer: A survivors guides to beating cancer and changing your life for the better

Beating Breast Cancer: A survivors guides to beating cancer and changing your life for the better


This book contains proven steps and strategies on how to help your body help itself by providing it with essential nutrients and removing those that have negative results. This book will also show you how and why your emotions play a significant part in disease and healing. As well as how taking charge of your life helps your body heal.

Chicken Soup for the Soul: Hope & Healing for Your Breast Cancer Journey: Surviving and Thriving During and After Your Diagnosis and Treatment

Chicken Soup for the Soul: Hope & Healing for Your Breast Cancer Journey: Surviving and Thriving During and After Your Diagnosis and Treatment
by Dr. Julie Silver (Author)


Chicken Soup for the Soul: Hope & Healing for Your Breast Cancer Journey will encourage comfort and encourage breast cancer patients and survivors with its inspiring stories and helpful medical information.

A support group from breast cancer diagnosis through treatment to rehabilitation and recovery, this book combines inspiring Chicken Soup for the Soul stories written just for this book and accessible leading-edge medical information from Dr. Julie Silver of Harvard Medical School. Patients and survivors will find comfort, strength and hope.

The Mayo Clinic Breast Cancer Book

The Mayo Clinic Breast Cancer Book
by the breast-health experts at Mayo Clinic Cancer Center (Author)


From the breast health experts at Mayo Clinic comes a guide to the many aspects of breast cancer—from prevention, to care and coping, to survival, to living with hope.

The Mayo Clinic Breast Cancer Book is the trusted resource for anyone wanting reliable information about this dreaded disease. Mayo Clinic set out to provide comprehensive and up-to-date facts in easy-to-understand language. They've succeeded in this handbook for those who've been diagnosed, or for those who want to give sensitive and helpful support to someone with breast cancer. The Mayo Clinic Breast Cancer Book stands out for its tone of companionship, as well as for the many patient stories that appear throughout the book. 

This straightforward yet approachable resource will empower all who are...

Breast Cancer (2015): 150 Latest & Illustrated Questions & Answers

Breast Cancer (2015): 150 Latest & Illustrated Questions & Answers


Why this book -- what is so exciting in the field of breast cancer? Take a look:
• Many early breast cancers, with timely and appropriate treatments, are now curable.
• The five-year survival rate of cancers confined to the milk ducts and milk lobules (DCIS & LCIS) has gone up to 100%.The five-year survival of Stage 1 (larger tumor or lymph node-positive tumor) has gone up to almost 90%.
• Combination of 3-D and Digital Mammograms Reduces False Positive Mammograms by 14% & Weeds out Invasive Ductal Carcinoma by 39 %.
• For the first time FDA labels a promising & new breast cancer drug the title of "Breakthrough" drug which doubles Progression Free Survival and extends overall survival (Ch:13).
• Do Aspirin, Ibuprofen, Advil, Aleve...Help Reduce...

© 2014 BrightSurf.com